FDA guidance
S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
FDA guidance · Final · issued May 18, 2012
Key facts
| Title | S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals |
|---|---|
| Status | Final |
| Issue date | May 18, 2012 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2009-D-0573 |
| Open for comment | No |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents